Mai 22, 2026
Medtech in Germany
Made in Germany: Precision Under Pressure
Germany built the world's most respected medical device industry on engineering excellence and Mittelstand grit. Now, regulatory overload, soaring costs, and global competition are testing whether "Made in Germany" can hold its ground.
2023
- €55bn Total revenue
- 265k Employees in the sector
- 68% Export rate
- €27bn in exports
In the clean rooms and precision workshops stretching from Bavaria's industrial heartland to the cluster networks around Hamburg and Aachen, Germany's medical technology industry has long embodied what the country does best: meticulous engineering, relentless quality, and world-leading export ambition. With 13,500 manufacturers, over 265,000 employees, and revenues of roughly €55 billion in 2023, the sector ranks among the country's most strategically vital industries — and among the most globally admired.
Yet behind that impressive façade, something more uncomfortable is unfolding. Smaller companies are quietly moving research abroad. Regulatory compliance costs are spiraling. Energy remains expensive. And the competitive landscape — from nimble American device makers to heavily subsidized Chinese manufacturers — is shifting faster than policy in Berlin can respond.
The question facing German medtech in 2026 is no longer whether challenges exist. It is whether the industry's storied foundations are strong enough to weather them.
The Industry’s Power
Market position: Germany accounts for nearly 27 percent of the European medical technology market — by far the largest share on the continent — and its exports reached €27.4 billion in 2023, with the United States and China the dominant non-European destinations.
And then there is the manufacturing culture itself. Apprenticeship-trained engineers, ISO-certified production lines, and a deep institutional commitment to precision manufacturing have given the "Made in Germany" label genuine commercial weight. Hospitals and healthcare systems around the world pay a premium for German devices because that premium typically translates into reliability.
Mounting Pressure
Germany’s challenges accumulating on every front
Speak to medtech executives in Germany today, and a remarkably consistent list of grievances emerges. They span regulation, economics, demographics, and geopolitics — a confluence of pressures that no single policy lever can resolve.
1 The MDR compliance burden
The EU Medical Device Regulation, phased in since 2021, imposes dramatically stricter requirements for clinical evidence, post-market surveillance, and traceability. For large multinationals, the costs are significant but manageable. For the Mittelstand, they can be existential. Recertification backlogs at notified bodies have left some devices in legal limbo, and smaller manufacturers — who lack dedicated regulatory teams — are bearing a disproportionate share of the administrative load.
2 Energy and production costs
Germany's industrial energy prices remain among the highest in the developed world, a structural disadvantage that sharpened dramatically after the loss of cheap Russian gas. Energy-intensive manufacturing processes — precision casting, sterilization, cleanroom operation — are especially vulnerable. A 2025 survey found that 35 percent of German industrial firms were investing abroad primarily to cut costs, the highest proportion since 2008.
3 Skilled labor shortages
Germany's demographic challenge is particularly acute in technical disciplines. Approximately 628,000 positions remained unfilled across the German economy in mid-2025, with engineering, healthcare technology, and IT roles among the most critical gaps. For medtech manufacturers, attracting and retaining precision engineers and regulatory specialists has become a persistent operational constraint, with small firms at a structural disadvantage relative to large corporations in competing for talent
4 Relocation and R&D erosion
The pressures above are producing a worrying behavioral shift. A 2025 BDI survey found that nearly one in three large industrial companies had relocated or were planning to relocate R&D operations abroad, with 60 percent citing high costs as the primary driver. For medtech specifically, this represents a slow hollowing-out of the innovation pipeline — precisely the area where Germany's long-term competitive advantage is most vulnerable.
5 PFAS and materials regulation
A proposed blanket restriction on per- and polyfluoroalkyl substances (PFAS) under the EU's REACH regulation poses a specific threat to medical device manufacturing. PFAS compounds — prized for their durability, chemical resistance, and biocompatibility — are integral to catheters, implants, surgical coatings, and diagnostic equipment. Industry associations warn that a categorical ban, without sector-specific exemptions, could trigger supply shortages for critical devices with no viable substitutes in the near term.
6 Global competitive pressure
The United States continues to attract German investment with lower corporate taxes, cheaper energy, and active industrial incentive programs. Meanwhile, Chinese manufacturers — historically focused on low-cost commodity devices — are moving rapidly up the quality ladder, supported by substantial state investment. Germany's traditional moat of manufacturing precision and regulatory reputation remains real, but it is narrowing in certain product categories.
"Innovation bottlenecks and the relocation of research projects abroad are often the result. Smaller manufacturers in particular are suffering — and planning to move activities abroad."
Digital Transformation
AI and digitalization: opportunity meeting hesitation
The medtech industry globally is in the early stages of integrating artificial intelligence into both products and manufacturing processes. Germany's sector is no exception — but its adoption trajectory reflects the broader caution of an industry built on regulatory certainty and proven reliability.
On the operational side, AI-driven quality inspection, predictive maintenance, and supply chain optimization offer genuine efficiency gains for German manufacturers constrained by high labor costs. These applications carry low regulatory risk and increasingly clear return-on-investment cases. The more visible ambition — embedding AI into diagnostic devices and software-as-a-medical-device (SaMD) applications — remains more complex, requiring new evidence standards and reimbursement frameworks that regulatory bodies are still developing.
Germany's hospital reform, underway since 2025, and growing federal investment in digital health infrastructure are creating a more receptive domestic market for digital medical technology. The EU4MEDTECH project, backed by €7.7 million in EU funding, is specifically aimed at streamlining regulatory pathways for innovative devices. These are encouraging signals, but the gap between AI's transformative potential and its actual clinical deployment remains significant.
Patent leadership: Germany registered more medtech patents with the European Patent Office in 2023 than any other EU member state — a sign that the innovation base remains robust even as commercialization faces headwinds.
Supply Chain
Trade tensions and the fragility of global sourcing
German medtech manufacturers, like their peers worldwide, were reminded during the pandemic that global supply chains carry systemic risks that cost-optimization alone cannot address. The lesson is being reinforced by rising trade tensions and shifting tariff regimes, particularly between the United States and China.
Companies that source components from China — semiconductor elements for imaging equipment, rare earth materials, specialized polymers — have seen input costs rise and lead times grow less predictable. The German Supply Chain Due Diligence Act (LkSG), which came into force in 2023, adds another compliance dimension: manufacturers must now audit and document the social and environmental practices of their suppliers, a requirement that falls hardest on companies with complex multi-tier supply networks.
The response across the industry has been mixed. Some manufacturers are pursuing nearshoring, relocating component sourcing to Central and Eastern Europe. Others are building strategic inventory buffers. A few are investing in vertical integration — bringing previously outsourced processes in-house. All three strategies involve cost and complexity tradeoffs that test the margins of Mittelstand-scale operations.
Looking ahead
Resilience factors and the path forward
Germany's medtech industry enters this period of pressure from a position that, despite its difficulties, retains genuine strength. The cluster networks, university hospitals, and apprenticeship-trained workforce represent durable competitive assets that rivals cannot easily replicate. The reputation of German devices in international markets — earned over decades — still commands commercial premiums.
Several structural factors offer grounds for cautious optimism. The German government's 2025 hospital reform is redesigning care delivery in ways that create demand for new device categories, particularly in outpatient and digital health settings. The European Commission's amendments to MDR and IVDR transition timelines have bought smaller manufacturers breathing room. And Germany's position at the center of European medtech cluster networks — with roughly 50 regional hubs — creates collaborative pathways for R&D investment that individual companies could not sustain alone.
The more difficult question is whether policy reform can keep pace with competitive pressure. The businesses most at risk — the specialized Mittelstand firms that form the industry's innovation backbone — are also the least able to absorb prolonged uncertainty. If regulatory burdens continue to outpace support, and if energy cost disadvantages persist without structural remedy, the quiet erosion of R&D capacity and production investment will compound into something harder to reverse.
In summary:
Germany's medical technology sector faces a genuinely difficult decade. The combination of MDR compliance costs, high energy prices, skilled labor shortages, and intensifying global competition creates a pressure environment unlike anything the industry has navigated in recent memory.
But the foundations — engineering culture, research infrastructure, cluster ecosystems, export reputation — have not dissolved. The industry's trajectory will depend heavily on whether government policy, at both the German and EU level, can reduce friction without sacrificing the regulatory standards that give "Made in Germany" its meaning. The medtech sector will need both reform and resilience in equal measure.
Source: MedTech Media Europe ©